- West Pharma’s 2025 adjusted earnings per share (EPS) forecast is lower than expected, with a range of $6.00 to $6.20 compared to the estimate of $7.44.
- In the fourth quarter, adjusted EPS was $1.82, slightly higher than the estimate of $1.72 but slightly lower than last year’s $1.83.
- The company reported net sales of $748.8 million for the fourth quarter, a 2.3% increase year-over-year, beating the estimate of $740.5 million.
- Proprietary Products net sales increased by 3.4% year-over-year to $613.9 million, exceeding the estimate of $599.6 million.
- Contract Manufacturing net sales decreased by 2.5% year-over-year to $134.9 million, falling short of the estimate of $141.4 million.
- Adjusted operating income for the fourth quarter was $162.8 million, a 1.8% increase from last year and above the estimate of $152.8 million.
- For the full year 2025, West Pharma expects net sales to range between $2.875 billion and $2.905 billion.
- Foreign currency exchange rates are anticipated to create a $75 million headwind for full-year 2025 net sales.
- The company expects continued momentum in its Proprietary Products segment, with growth in Biologics, Generics, Annex 1, and GLP-1 categories.
- Market analysis shows 10 buy recommendations, 4 hold recommendations, and no sell recommendations for West Pharma stock.
West Pharmaceutical Services Inc on Smartkarma
Analysts on Smartkarma, such as Baptista Research, are closely covering West Pharmaceutical Services Inc. In their recent report titled “West Pharmaceutical Services: Expanding Capacity in High-Value Product Lines & Unlocking Commercial Manufacturing Potential! – Major Drivers,” Baptista Research delves into the company’s third-quarter earnings, noting a balance of consistent performance and ongoing challenges in the market. The report emphasizes West Pharmaceutical’s effective execution of strategic initiatives amidst customer destocking and demand fluctuations. Baptista Research aims to assess various factors influencing the company’s future stock price through an independent valuation using the Discounted Cash Flow (DCF) methodology.
A look at West Pharmaceutical Services Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
West Pharmaceutical Services Inc, a company specializing in providing key services for the pharmaceutical industry, is projected to have a promising long-term outlook based on its Smartkarma Smart Scores. With solid scores in Resilience and Momentum, the company is positioned well to weather challenges and benefit from positive market trends. Its focus on growth and strong performance in these key areas indicate a potential for sustained success in the future.
Known for its value-added services in bringing new drug therapies and healthcare products to global markets, West Pharmaceutical Services Inc also demonstrates a balanced approach with moderate scores in Value and Dividend. Its emphasis on growth and resilience, along with a strong momentum, underlines the company’s strategic positioning in the industry, suggesting a positive trajectory for long-term growth and success.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
